| P2093 | author name string | Paul M Roman | |
| | Carrie B Oser | |
| P2860 | cites work | Naltrexone treatment in a jail work-release program. | Q52270310 |
| | Evidence-based treatment for opiate-dependent clients: availability, variation, and organizational correlates. | Q52290325 |
| | Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. | Q52894361 |
| | Naltrexone and coping skills therapy for alcohol dependence. A controlled study | Q67587951 |
| | A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse | Q73230281 |
| | Naltrexone and alcohol dependence. Role of subject compliance | Q73665563 |
| | Naltrexone in the treatment of alcohol dependence | Q77347366 |
| | Organizational innovation: the influence of individual, organizational, and contextual factors on hospital adoption of technological and administrative innovations | Q77491191 |
| | Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation | Q28140216 |
| | The effects of naltrexone on alcohol and cocaine use in dually addicted patients | Q28369822 |
| | Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors | Q31041707 |
| | An institutional perspective on rational myths and organizational change in health care | Q33550412 |
| | Obstacles to answering doctors' questions about patient care with evidence: qualitative study | Q34010476 |
| | Disseminating innovations in health care | Q34190848 |
| | Naltrexone in the treatment of alcohol dependence | Q34241680 |
| | Organizational-level predictors of adoption across time: naltrexone in private substance-use disorders treatment centers. | Q34711509 |
| | A systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence | Q34929254 |
| | The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters | Q35792939 |
| | HIV testing in correctional agencies and community treatment programs: the impact of internal organizational structure | Q35865698 |
| | Innovation adoption in substance abuse treatment: exposure, trialability, and the Clinical Trials Network. | Q36627877 |
| | Prescribing new drugs: qualitative study of influences on consultants and general practitioners | Q37086212 |
| | Reviewing the behavioral science knowledge base on technology transfer. Introduction | Q40965449 |
| | Naltrexone in the treatment of alcoholism: a clinical review | Q41136549 |
| | Adoption and implementation of new technologies in substance abuse treatment. | Q44033265 |
| | Substance user treatment program quality: selected topics | Q44103409 |
| | Modeling the use of innovations in private treatment organizations: the role of absorptive capacity | Q47293358 |
| | Assessing organizational readiness for change | Q48631182 |
| | Innovation in nursing homes: which facilities are the early adopters? | Q50126681 |
| | Naltrexone in addicted business executives and physicians | Q52269910 |
| | Naltrexone treatment for addicted health-care professionals: a collaborative private practice experience. | Q52270308 |
| P433 | issue | 4 | |
| P921 | main subject | naltrexone | Q409587 |
| | substance P | Q411041 |
| | substance abuse | Q3184856 |
| P304 | page(s) | 433-442 | |
| P577 | publication date | 2007-11-07 | |
| P1433 | published in | Journal of Substance Abuse Treatment | Q15762042 |
| P1476 | title | A categorical typology of naltrexone-adopting private substance abuse treatment centers | |
| P478 | volume | 34 | |